Taysha Gene Therapies
NASDAQ: TSHATexas, US · Founded 2019 · Delaware corporation · 2 known investors
Taysha Gene Therapies develops and commercializes gene therapies for monogenic diseases of the central nervous system, serving patients with rare and larger CNS conditions. Its lead clinical program targets Rett syndrome, alongside a broader pipeline of CNS programs.
BiotechDeep TechDigital HealthHealthtechMedical Devices
Founders & leadership
Taysha Gene Therapies was founded in 2019 by R.A. Session II.
RS
R.A. Session IIFounder
SP
Sean P. NolaninChief Executive Officer and Board ChairmanNolan previously led AveXis Inc. as President and CEO from 2015 to 2018, and held senior roles including Chief Business Officer at InterMune, Chief Commercial Officer at Reata Pharmaceuticals, and President of Lundbeck Inc., the company's US affiliate formerly known as Ovation Pharmaceuticals. His earlier work at Lundbeck spanned product development, global project management, and commercial integration following the Ovation acquisition.
Board
PB
SN
Sean NolanBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$294M disclosed across 4 rounds · 2020–2023
▶$150MraisedAug 2023 · 42 investors · BiotechnologyRule 506(b)
▶$150MraisedAug 2023 · 42 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Phillip DonenbergDirector
- Sean P. NolanExecutive Officer, Director
- Laura Sepp-LorenzinoDirector
- Sean StalfortDirector
- Kamran AlamExecutive Officer
- Kathleen ReapeDirector
- Sukumar NagendranExecutive Officer, Director
- Offering amount
- $150M
- Amount sold
- $150M
- Finders' fees
- $9M
- Placement agents
- Jefferies LLC
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$30MraisedNov 2022 · 1 investors · BiotechnologyRule 506(b)
▶$30MraisedNov 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Laura Sepp-LorenzinoDirector
- RA Session IIExecutive Officer, Director
- Kathleen ReapeDirector
- Kamran AlamExecutive Officer
- Phillip B. DonenbergDirector
- Paul B. ManningDirector
- Sean P. NolanDirector
- Suyash PrasadExecutive Officer
- Sukumar NagendranDirector
- Offering amount
- $30M
- Amount sold
- $30M
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$96MraisedAug 2020 · 26 investors · BiotechnologyRule 506(b)
▶$96MraisedAug 2020 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sean NolanDirector
- Sukumar NagendranDirector
- Suyash PrasadExecutive Officer
- Kamran AlamExecutive Officer
- R. A. Session IIExecutive Officer, Director
- Paul B. ManningDirector
- Offering amount
- $96M
- Amount sold
- $96M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$18MraisedMay 2020 · 9 investors · BiotechnologyRule 506(b)
▶$18MraisedMay 2020 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- R.A. Session IIExecutive Officer, Director
- Paul B. ManningDirector
- Sean NolanDirector
- Offering amount
- $30M
- Amount sold
- $18M
- Finders' fees
- $435K
- Placement agents
- Chardon Capital Markets LLC
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapSeeking Alpha29 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.
Simply Wall St24 shared keywordsSimply Wall St is a stock analysis platform that provides portfolio insights, stock discovery tools, and market alerts for individual investors. The service offers institutional-grade financial data visualization and analysis across 120,000 global stocks.
Robinhood24 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Tradingview21 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Companies competing with Taysha Gene Therapies for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Taysha Gene Therapies do?
- Taysha Gene Therapies develops and commercializes gene therapies for monogenic diseases of the central nervous system, serving patients with rare and larger CNS conditions. Its lead clinical program targets Rett syndrome, alongside a broader pipeline of CNS programs.
- Who founded Taysha Gene Therapies?
- Taysha Gene Therapies was founded by R.A. Session II in 2019.
- Who are Taysha Gene Therapies's investors?
- Taysha Gene Therapies's investors include GV (Google Ventures), PBM Capital.
- How much funding has Taysha Gene Therapies raised?
- Taysha Gene Therapies has disclosed $294M raised across 4 rounds.
- Where is Taysha Gene Therapies headquartered?
- Taysha Gene Therapies is headquartered in Texas, US.